Aquestive Therapeutics (NASDAQ:AQST) Given “Buy” Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Aquestive Therapeutics (NASDAQ:AQST) in a report released on Monday morning, The Fly reports. The brokerage currently has a $14.00 price objective on the stock, up from their prior price objective of $12.00.

Several other analysts have also issued reports on the stock. Zacks Investment Research raised shares of Aquestive Therapeutics from a hold rating to a buy rating and set a $6.00 price target on the stock in a research report on Monday, November 11th. Wedbush reaffirmed a buy rating and issued a $37.00 price objective on shares of Aquestive Therapeutics in a report on Monday, November 25th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of Buy and an average price target of $18.40.

Shares of NASDAQ:AQST opened at $8.74 on Monday. The company has a 50-day moving average price of $5.03 and a two-hundred day moving average price of $4.17. Aquestive Therapeutics has a twelve month low of $2.95 and a twelve month high of $10.00.

Several large investors have recently added to or reduced their stakes in the stock. Wedbush Securities Inc. bought a new position in Aquestive Therapeutics in the 2nd quarter worth about $297,000. JPMorgan Chase & Co. lifted its holdings in shares of Aquestive Therapeutics by 728.6% in the second quarter. JPMorgan Chase & Co. now owns 22,761 shares of the company’s stock worth $93,000 after buying an additional 20,014 shares in the last quarter. Canada Pension Plan Investment Board bought a new position in shares of Aquestive Therapeutics in the second quarter valued at approximately $105,000. Jacobs Levy Equity Management Inc. bought a new position in shares of Aquestive Therapeutics in the second quarter valued at approximately $361,000. Finally, Paloma Partners Management Co purchased a new position in Aquestive Therapeutics during the second quarter valued at approximately $213,000. Institutional investors own 54.25% of the company’s stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery in the United States and internationally.

Recommended Story: What are the qualifications of a portfolio manager?

The Fly

Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.